EE04431B1 - Bensamidiini derivaadid ja nende kasutamine LTB-4antagonistliku mõjuga ravimitena - Google Patents

Bensamidiini derivaadid ja nende kasutamine LTB-4antagonistliku mõjuga ravimitena

Info

Publication number
EE04431B1
EE04431B1 EEP199900086A EE9900086A EE04431B1 EE 04431 B1 EE04431 B1 EE 04431B1 EE P199900086 A EEP199900086 A EE P199900086A EE 9900086 A EE9900086 A EE 9900086A EE 04431 B1 EE04431 B1 EE 04431B1
Authority
EE
Estonia
Prior art keywords
ltb
antagonist drugs
benzamidine derivatives
benzamidine
derivatives
Prior art date
Application number
EEP199900086A
Other languages
English (en)
Estonian (et)
Other versions
EE9900086A (et
Inventor
Michael Jennewein Hans
John Montague Meade Christopher
Schromm Kurt
Anderskewitz Ralf
Renth Ernst-Otto
Birke Franz
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of EE9900086A publication Critical patent/EE9900086A/xx
Publication of EE04431B1 publication Critical patent/EE04431B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
EEP199900086A 1996-09-10 1997-09-09 Bensamidiini derivaadid ja nende kasutamine LTB-4antagonistliku mõjuga ravimitena EE04431B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636689A DE19636689A1 (de) 1996-09-10 1996-09-10 Neue Benzamidinderivate
PCT/EP1997/004921 WO1998011062A1 (de) 1996-09-10 1997-09-09 Benzamidinderivate und ihre verwendung als arzneimittel mit ltb4-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
EE9900086A EE9900086A (et) 1999-10-15
EE04431B1 true EE04431B1 (et) 2005-02-15

Family

ID=7805125

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900086A EE04431B1 (et) 1996-09-10 1997-09-09 Bensamidiini derivaadid ja nende kasutamine LTB-4antagonistliku mõjuga ravimitena

Country Status (31)

Country Link
US (2) US6197824B1 (ko)
EP (2) EP0929516B1 (ko)
JP (2) JP4150427B2 (ko)
KR (1) KR20000036005A (ko)
CN (1) CN1104412C (ko)
AR (1) AR009741A1 (ko)
AT (2) ATE266630T1 (ko)
AU (1) AU727900B2 (ko)
BG (1) BG63938B1 (ko)
BR (1) BR9712816A (ko)
CA (1) CA2262566C (ko)
CO (1) CO4900032A1 (ko)
CZ (1) CZ297252B6 (ko)
DE (3) DE19636689A1 (ko)
DK (1) DK0929516T3 (ko)
EA (1) EA003245B1 (ko)
EE (1) EE04431B1 (ko)
ES (1) ES2184131T3 (ko)
HK (1) HK1020564A1 (ko)
HU (1) HUP9904367A3 (ko)
IL (1) IL128144A (ko)
NO (1) NO312239B1 (ko)
NZ (1) NZ334895A (ko)
PL (1) PL188012B1 (ko)
PT (1) PT929516E (ko)
SK (1) SK282432B6 (ko)
TR (1) TR199900501T2 (ko)
TW (1) TW378200B (ko)
UA (1) UA60315C2 (ko)
WO (1) WO1998011062A1 (ko)
ZA (1) ZA978045B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29066A (id) 1998-12-14 2001-07-26 Hoffmann La Roche Turunan fenilglisina
US6291531B1 (en) * 1999-10-07 2001-09-18 Boehringer Ingelheim Pharma Kg LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
DE19948428A1 (de) * 1999-10-07 2001-04-12 Boehringer Ingelheim Pharma Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
DE10052658A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Pyranosidderivate
DE10052333A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Sulfooxybenzamide
US6489359B2 (en) 2000-10-24 2002-12-03 Boehringer Ingelheim Pharma Kg Sulphoxybenzamides
US6528491B2 (en) 2000-10-24 2003-03-04 Boehringer Ingelheim Pharma Kg Pyranoside derivatives
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
US20030119901A1 (en) * 2001-07-14 2003-06-26 Boehringer Ingelheim Pharma Kg Pharmaceutical formulation containing an LTB4 antagonist
NZ530973A (en) * 2001-07-14 2006-07-28 Boehringer Ingelheim Pharma Pharmaceutical formulation containing an LTB4 antagonist
CN1658852A (zh) * 2001-08-31 2005-08-24 神经化学（国际）有限公司 用于治疗淀粉样变性的脒衍生物
DE10213350A1 (de) * 2002-03-26 2003-10-16 Boehringer Ingelheim Pharma Verwendung von LTB¶4¶Antagonisten in der Tiermedizin
US6921752B2 (en) * 2002-03-26 2005-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of LTB4 antagonists in veterinary medicine
RS20050390A (en) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
US8679288B2 (en) * 2008-06-09 2014-03-25 Lam Research Corporation Showerhead electrode assemblies for plasma processing apparatuses
CN106831611B (zh) * 2017-01-23 2019-06-21 北京化工大学 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用
EP3623368A4 (en) 2017-05-12 2021-04-07 Riken CLASS A GPCR BINDING COMPOUND MODIFIER
WO2020061688A1 (en) * 2018-09-24 2020-04-02 The University Of British Columbia Modulation of granzyme k activity in the treatment of skin conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5246965A (en) 1991-06-11 1993-09-21 Ciba-Geigy Arylethers, their manufacture and methods of treatment
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
PT902013E (pt) 1992-02-05 2002-06-28 Boehringer Ingelheim Pharma Novos derivados amidina sua preparacao e utilizacao como medicamento com actividade antagonista de ltb4
DE4219158A1 (de) * 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
DE4424714A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP0929516B1 (de) 2002-09-18
CN1230174A (zh) 1999-09-29
BG103219A (en) 1999-10-29
NO991131D0 (no) 1999-03-09
DE59711625D1 (de) 2004-06-17
HUP9904367A3 (en) 2001-11-28
ATE224363T1 (de) 2002-10-15
CZ297252B6 (cs) 2006-10-11
AU727900B2 (en) 2001-01-04
ZA978045B (en) 1998-03-10
PT929516E (pt) 2003-01-31
DK0929516T3 (da) 2003-01-13
JP4150427B2 (ja) 2008-09-17
AU4383897A (en) 1998-04-02
ATE266630T1 (de) 2004-05-15
HUP9904367A2 (hu) 2000-05-28
BR9712816A (pt) 1999-11-23
SK29699A3 (en) 2000-03-13
BG63938B1 (bg) 2003-07-31
EP1203764A1 (de) 2002-05-08
IL128144A (en) 2004-07-25
NO991131L (no) 1999-03-09
PL188012B1 (pl) 2004-11-30
DE59708278D1 (de) 2002-10-24
NZ334895A (en) 2000-09-29
JP2008266333A (ja) 2008-11-06
US6265612B1 (en) 2001-07-24
CO4900032A1 (es) 2000-03-27
NO312239B1 (no) 2002-04-15
KR20000036005A (ko) 2000-06-26
HK1020564A1 (en) 2000-05-12
TW378200B (en) 2000-01-01
CN1104412C (zh) 2003-04-02
EA199900279A1 (ru) 1999-08-26
PL332136A1 (en) 1999-08-30
EA003245B1 (ru) 2003-02-27
WO1998011062A1 (de) 1998-03-19
TR199900501T2 (xx) 1999-07-21
SK282432B6 (sk) 2002-02-05
ES2184131T3 (es) 2003-04-01
JP4288299B2 (ja) 2009-07-01
EP1203764B1 (de) 2004-05-12
DE19636689A1 (de) 1998-03-12
CZ82299A3 (cs) 1999-09-15
US6197824B1 (en) 2001-03-06
IL128144A0 (en) 1999-11-30
EE9900086A (et) 1999-10-15
CA2262566C (en) 2006-07-11
JP2001504087A (ja) 2001-03-27
CA2262566A1 (en) 1998-03-19
EP0929516A1 (de) 1999-07-21
UA60315C2 (uk) 2003-10-15
AR009741A1 (es) 2000-05-03

Similar Documents

Publication Publication Date Title
EE9900086A (et) Bensamidiini derivaadid ja nende kasutamine LTB-4 antagonistliku mõjuga ravimitena
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
FI20002103A (fi) Amidijohdannaisia ja nosiseptiiniantagonisteja
DK0789562T3 (da) Caffeinformulering med vedvarende afgivelse
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
DK0984773T3 (da) Farmaceutisk formulering med omeprazol
ATE243516T1 (de) Amoxicillin und clavulanat enthaltende arzneizubereitungen
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
BR9707501A (pt) Composto composição farmacêutica e uso do composto
BR9708902A (pt) Derivados de benzofurila e seu uso
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
BR9707808A (pt) Composto composição farmacêutica e uso do composto
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
HUP0104238A2 (en) Benzoxazole derivatives and drugs containing the same as the active ingredient and their use
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
IT1291823B1 (it) Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
NO953050D0 (no) Anvendelse av neurotensin-antagonister for fremstilling av diuretiske medikamenter

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120909